In 2019, entrepreneur Bryan Johnson began to experiment on himself by taking daily injections of rapamycin. This immunosuppressant drug is typically used to prevent organ rejection after transplants, but the 48-year-old technology entrepreneur and venture capitalist had a different goal ' to extend his life. He tested several protocols, experimenting with weekly, biweekly and other schedules. He tried 5-milligram doses as well as 6-mg and 10-mg ones. But in September 2024, Johnson decided to end his personal trial with rapamycin: the benefits didn't outweigh the drawbacks, which Johnson outlined in a post on social-media platform X. He had intermittent skin infections, high glucose levels and abnormalities in his blood lipid levels, plus a heightened resting heart rate. 'With no other underlying causes identified, we suspected Rapamycin, and since dosage adjustments had no effect, we decided to discontinue it entirely,' he wrote. Johnson, who sold his mobile-payment business...
learn more
